Elisabetta Bianchi

USPTO Granted Patents = 29 (Patent Applications = 16)

CIPO Patents = 2 (Patent Applications = 12)

EPO Patents = 12 (Patent Applications = 22)

Average Co-Inventor Count = 7.5

ph-index = 4

Forward Citations = 60(Granted Patents)

Location History:

Via Sabotino, IT (2010)
Pommezia, IT (2017)
Rome, IT (1993 - 2024)
Pomezia, IT (2015 - 2024)

Company Filing History:

18 out of 2,405

Merck Sharp + Dohme Corp.

patents

4 out of 28

Ra Pharmaceuticals, Inc.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.r.l.

patent

7. 1 out of 1

Istituto Di Ricerche Di Biologia Moleculare S.p.a.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

Whitehead Insitute of Biomedical Research

Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.p.a.

patents

15. 1 out of 410

Janssen Biotech, Inc.

patents

16. 1 out of 32

Protagonist Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 1993-2025

Loading Chart...

29 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12209145 - PCSK9 antagonist compounds (2025-01-28),

2. 12018057 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases (2024-06-25),

3. 12012468 - Cyclic polypeptides for PCSK9 inhibition (2024-06-18),

4. 11932705 - Cyclic polypeptides for PCSK9 inhibition (2024-03-19),

5. 11773150 - Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors (2023-10-03),

6. 11725036 - Modified lipidated relaxin B chain peptides and their therapeutic use (2023-08-15),

7. 11566057 - Long-acting co-agonists of the glucagon and GLP-1 receptors (2023-01-31),

8. 11530244 - Cyclic polypeptides for PCSK9 inhibition (2022-12-20),

9. 11505575 - Cyclic polypeptides for PCSK9 inhibition (2022-11-22),

10. 11492385 - Long-acting co-agonists of the glucagon and GLP-1 receptors (2022-11-08),

11. 11427616 - PCSK9 antagonist compounds (2022-08-30),

12. 11306125 - PCSK9 antagonists bicyclo-compounds (2022-04-19),

13. 10988524 - Modified relaxin B chain peptides and their therapeutic use (2021-04-27),

14. 10988523 - Modified lipidated Relaxin B chain peptides and their therapeutic use (2021-04-27),

15. 10961295 - Modified lipidated Relaxin B chain peptides and their therapeutic use (2021-03-30),

Title: Elisabetta Bianchi: Innovator in Pharmaceutical Patents from Pomezia, IT

Introduction

Elisabetta Bianchi is a prominent inventor based in Pomezia, Italy, known for her significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 29 patents, she has made substantial advancements in the development of compounds and treatments for various inflammatory diseases.

Latest Patents

Among her latest patents are two noteworthy innovations. The first involves PCSK9 antagonist compounds, which are essential for managing cholesterol levels. The second, titled "Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases," introduces novel peptide inhibitors aimed at treating conditions such as inflammatory bowel diseases. These patents illustrate her commitment to addressing critical health challenges through innovative solutions.

Career Highlights

Elisabetta Bianchi has had an impressive career, working with well-known companies such as Merck Sharp & Dohme Corporation and Ra Pharmaceuticals, Inc. Her work at these organizations not only underscores her expertise in the pharmaceutical industry but also highlights her role in advancing healthcare through innovative research and development.

Collaborations

Throughout her career, Elisabetta has collaborated with notable coworkers, including Antonello Pessi and Raffaele Ingenito. These partnerships have enabled her to enhance her research efforts, fostering a collaborative atmosphere that encourages innovation and the sharing of ideas among leading professionals in the field.

Conclusion

Elisabetta Bianchi's noteworthy contributions to pharmaceutical sciences through her patents demonstrate her dedication to improving health outcomes. With a strong foundation built on collaboration and innovation, she continues to influence the pharmaceutical landscape, setting the stage for future advancements in the treatment of various diseases. Her work not only highlights her individual achievements but also reflects the importance of teamwork in the field of research and development.

This text is generated by artificial intelligence and may not be accurate.